Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalcilib + aromatase inhibitor + capecitabine neoadjuvant therapy in HR-positive/HER2-negative early breast cancer
ChiCTR2400090076Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Fujian Medical University Union Hospital. Primary endpoint: objective response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400090076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090076.